Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, November 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform, and a replay will be available on the Events & Presentations page of the company’s investor relations website.
The announcement matters because it gives Helus Pharma a prominent forum to engage with healthcare investors and industry experts, potentially increasing visibility for its pipeline. The company is developing proprietary novel serotonergic agonists, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. These programs target a large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Participation in the Guggenheim conference could enhance the company’s profile among institutional investors and strategic partners, especially as it advances HLP003 through late-stage development. The webcast and replay offer broader access to the presentation, allowing stakeholders who cannot attend in person to hear directly from management. For a clinical-stage company like Helus Pharma, such exposure can be important for building awareness and credibility in a competitive sector.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. More information about the company is available at www.helus.com. The full press release can be viewed at https://ibn.fm/LrRvm.
The press release was distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire offers services including editorial syndication to 5,000+ outlets and social media distribution. Terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
